Germ line BAX alterations are infrequent in Li-Fraumeni syndrome

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 8, 2004, Pages 1403-1406

  Barlow, Jason W ^a,b   Mous, Marieke ^d   Wiley, Joe C ^a   Varley, Jennifer M ^e   Lozano, Guillermina ^f   Strong, Louise C ^f   Malkin, David ^a,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BAX GENE; CANCER FAMILY; CELL LINE; CONTROLLED STUDY; FAMILIAL CANCER; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GERM LINE; HUMAN; HUMAN CELL; LEUKOCYTE; PRIORITY JOURNAL; TP53 GENE;

ALLELES; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; INCIDENCE; LI-FRAUMENI SYNDROME; MALE; PEDIGREE; POLYMORPHISM, GENETIC; PROGNOSIS; RISK ASSESSMENT; SAMPLING STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4043089394     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Li FP, Fraumeni JF Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969a;43:1365-73.
2. Li FP. Cancer families: Human models of susceptibility to neoplasia. Cancer Res 1988;48:5381-6.
3. Lustbader ED, Williams WR, Bondy ML, Strom S, Strong LC. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet 1992;54:344-56.
4. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90:606-11.
5. Malkin D, Li FP, Strong LC, et al. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
6. Varley JM, McGown G, Thorncroft M, et al. Germline mutations of TP53 in Li-Fraumeni families: An extended study of 39 families. Cancer Res 1997;57:3245-52.
7. Portwine C, Lees J, Verselis S, Li FP, Malkin D. Absence of germline p16(INK4a) alterations in p53 wild type Li-Fraumeni syndrome families. J Med Genet 2000;37:1-4.
8. Burt EC, McGown G, Thorncroft M, James LA, Birch JM, Varley JM. Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li-Fraumeni syndrome. Br J Cancer 1999;80:9-10.
9. Brown LT, Sexsmith E, Malkin D. Identification of a novel PTEN intronic deletion in Li-Fraumeni syndrome and its effect on RNA processing. Cancer Genet Cytogenet 2000;123:65-8.
10. Stone JG, Eeles RA, Sodha N, Murday V, Sheriden E, Houlston RS. Analysis of Li-Fraumeni syndrome and Li-Fraumeni-like families for germline mutations in BCL10. Cancer Lett 1999;147:181-5.
11. Bougeard G, Limacher J, Martin C, et al. Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome. J Med Genet 2001;38:253-6.
12. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999;286:2528-31.
13. Lee SB, Kim SH, Bell DW, et al. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni syndrome. Cancer Res 2001;61:8062-7.
14. Vahteristo P, Tamminen A, Karvinen P, et al. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 2001;61:5718-22.
15. Plummer SJ, Santibanez-Koref M, Kurosaki T, et al. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family. Oncogene 1994;9:3273-80.
16. Barel D, Avigad S, Mor C, Fogel M, Cohen IJ, Zaizov R. A novel germ-line mutation in the noncoding region of the p53 gene in a Li-Fraumeni family. Cancer Genet Cytogenet 1998;103:1-6.
17. Avigad S, Barel D, Blau O, et al. A novel germ line p53 mutation in intron 6 in diverse childhood malignancies. Oncogene 1997;14:1541-5.
18. Hsu Y-T, Youle RJ. Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J Biol Chem 1998;273:10777-83.
19. Antonsson B, Montessuit S, Sanchez B, Martinou JC. Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells. J Biol Chem 2001;276:11615-23.
20. Mikhailov V, Mikhailova M, Pulkrabek DJ, Dong Z, Venkatachalam MA, Saikumar P. Bcl-2 prevents Bax oligomerization in the mitochondrial outer membrane. J Biol Chem 2001;276:18361-74.
21. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human BAX gene. Cell 1995;80:293-9.
22. Chou D, Miyashita T, Mohrenweiser HW, et al. The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. Cancer Genet Cytogenet 1996;88:136-40.
23. Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997;275:967-9.
24. Meijerink JPP, Smeters TFCM, Sloetjes AW, Linders EHP, Mensink EJBM. BAX mutations in cell lines derived from hematological malignancies. Leukaemia 1995;9:1828-32.
25. Apte SS, Mattei M, Olsen BR. Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and isolation of a novel alternatively spliced transcript, BAXδ. Genomics 1995;26:592-4.
26. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-56.
27. Suzuki M, Youle RJ, Tjandra N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 2000;103:645-54.
28. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.